( CAMBRIDGE Mass.--(BUSINESS WIRE)--Jun ...)Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data,at Society Of Nuclear Medicine 2007 Annual Meeting,Health

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 4, 2007 - Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today that the company will present the results of several preclinical studies at the 54th annual meeting of the Society of Nuclear Medicine (SNM) in Washington, D.C. The presentations include data on Azedra(TM) (Ultratrace (131)I-MIBG), the company's clinical-stage, targeted radiotherapeutic candidate for the treatment of malignant neuroendocrine tumors; Zemiva, its lead molecular imaging pharmaceutical for imaging cardiac ischemia; and MIP-190, its molecular imaging pharmaceutical candidate that targets angiotensin converting enzyme for the detection of heart failure and vascular inflammatory disease. Data on the company's radiolabeled small molecule molecular imaging pharmaceutical, MIP-1072, for the detection and staging of prostate cancer, were presented on June 3rd. -0-

Abstract Title: Formulation comparisons and pharmacokinetics of high

                specific activity Ultratrace 131I-Iobenguane (mIBG)

                for therapy


Authors:        J. F. Kronauge(a1), J. A. Barrett(1), J. Qi(1),

                H. Mok(1), D. H. Hunter(2), C. Bensimon(4),

                S. Oelsner(4), J. P. Norenberg(3), T. Anderson(3),

                S. Gallo(1), S. M. Hiller(1), J. Joyal(1),

                N. S. Lee(1) and J. W. Babich(1);

                1. Molecular Insight Pharmaceuticals, Inc., Cambridge,

                Massachusetts; 2. University of Western Ontario,

                London, Ontario, Canada; 3. University of New Mexico,

                Albuquerque, New Mexico and 4. MDS Nordion, Kanata,

                Ontario, Canada.


Reference #:    335357


Publication No.: 1316 - Scientific Poster Session


Poster Section:  Dosimetry/Radiobiology Posters


Session Info:   "Meet the Author" II: Neurosciences, General Clinical

                Specialties, and Radiopharmaceutical Chemistry Posters

                Monday, June 4

    
'"/>




Page: 1 2 3 4 
Related medicine technology :

1. Molecular Target of Bradmers Neuradiab Further Validated by
Independent Findings
2. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data
on Molecular Imaging Pharmaceutical for Prostate Cancer
3. Amsterdam Molecular Therapeutics BV to present preclinical
proof-of-concept data on its gene therapy AMT-020 to treat acute
intermittent porphyria
4. DNA Therapeutics Reports a Novel Mechanism of Action and a
Biomarker of its Lead Molecule Dbait That Open an Innovative
Pathway-Targeting in Molecular Cancer Therapy
5. Avid Announces Results of AV-1 Molecular Imaging Agent for
Alzheimers Disease Presented at AD/PD Meeting
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug
Candidates to Be Presented at Upcoming EULAR Meeting
7. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively
Licensed to Subsidiary, RXi Pharmaceuticals, Described in
Peer-Reviewed Journal
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia
Program at International Society On Thrombosis and Haemostasis
(ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the
Clinical Trial of MediGenes Cancer-Killing Virus in Press
Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity
and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes
Association Conference